MedTrace Logo

PCSK9 Inhibitor for Intracranial Atherosclerotic Symptomatic Stenosis

NCT07119918 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5276

Last updated 2025-08-13

No results posted yet for this study

Summary

An investigator-initiated, prospective, multicenter, randomized, double-blind, placebo-controlled trial comparing the 1-year incidence of stroke in patients with AIS or TIA within 7 days who are treated with either placebo or Recaticimab.

Conditions

  • Symptomatic Intracranial Atherosclerotic Stenosis

Interventions

DRUG

Recaticimab

Recaticimab 300mg subcutaneous Q8W for 1 year.

DRUG

Placebo

Matched placebo subcutaneous Q8W for 1 year.

Sponsors & Collaborators

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Yamei Tang · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-01
Primary Completion
2029-12-01
Completion
2029-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07119918 on ClinicalTrials.gov